During the current pandemic of COVID-19, numerous manifestations and complications have developed. Patients with COVID-19 are at high risk of fungal infections, such as mucormycosis, that may result directly from COVID-19 infection and/or as a side effect of the drugs used in COVID-19 treatment protocol, such as dexamethasone, hydroxychloroquine, and antibiotics. In this report, we described a series of 14 cases with maxillary mucormycosis osteomyelitis in immediate post-COVID-19 patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624954 | PMC |
| http://dx.doi.org/10.3390/diagnostics11112050 | DOI Listing |
Publication Analysis
Top Keywords
maxillary mucormycosis
8
mucormycosis osteomyelitis
8
covid-19
5
osteomyelitis post
4
post covid-19
4
covid-19 patients
4
patients series
4
series fourteen
4
fourteen cases
4
cases current
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!